Trials / Terminated
TerminatedNCT06188208
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
A Phase 1, Open-Label, 2-Part, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of the STAT3 Inhibitor VVD-130850 as Single Agent and in Combination With Checkpoint Inhibition in Participants With Advanced Solid and Hematologic Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 132 (actual)
- Sponsor
- Vividion Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VVD-130850 | Oral tablets |
| DRUG | Pembrolizumab | IV infusion |
Timeline
- Start date
- 2024-01-05
- Primary completion
- 2025-12-21
- Completion
- 2025-12-21
- First posted
- 2024-01-03
- Last updated
- 2026-03-30
Locations
20 sites across 3 countries: United States, Australia, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06188208. Inclusion in this directory is not an endorsement.